1) Introduction

 

2) Executive Summary

 

3) Target Background

 

4) Target validation

 

• Clinical Success of Anti-IL17 Antibodies

 

• Non-Clinical Target Validation

 

• Clinical Lead Indication for RORgamma Antagonists

 

• Target-related Potential Safety Concerns

 

5) Drug Discover Approaches & Technologies

 

• Drug Discovery Collaboration

 

• Commercial Value of RORgamma Modulator Drug Discovery Collaborations

 

• R&D Timelines for Discovery of RORgamma Antagonists in Partnership Programs

 

• Strategies for the Discovery of Nuclear Receptor Ligands

 

6) Competitive Landscape of RORgamma Modulators

 

• RORgamma Antagonists for Inflammatory and Autoimmune Diseases

 

• Agonists of RORgamma for Cancer

 

7) Corporate Stakeholders

 

• Unpartnered Technology Companies

 

• Partnerships

 

• Unpartnered Pharmaceutical Companies

 

8) References?

 

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists



Tables in the report

 

Table 1: Disease Models Used for Non-Clinical Studies of RORgamma Antagonists

Table 2: Overview of Non-Clinical Studies of RORgamma Antagonists in Psoriasis Models

Table 3: Overview of Non-Clinical Studies of RORgamma Antagonists in Multiple Sclerosis Models

Table 4: Overview of Non-Clinical Studies of RORgamma Antagonists in Arthritis Models

Table 5: Overview of Non-Clinical Studies of RORgamma Antagonists in Inflammatory Bowel Disease and Ulcerative Colitis Models

Table 6: Overview of Non-Clinical Studies of RORgamma Antagonists in Systemic Lupus Erythematosus Models

Table 6: Overview of Partnership Agreements for RORgamma Modulators

Table 7: Special Collaborations for Discovery of RORgamma Antagonists

Table 8: Financial Terms of Partnership Agreements for RORgamma Modulators

Table 9: R&D Timeline for Discovery of RORgamma Antagonists in Partnership Programs

Table 10: Technologies for Discovery of RORgamma Antagonists

Table 11: RORgamma(T) Antagonists / Inverse Agonists in Clinical Development

Table 12: RORgamma(T) Antagonists / Inverse Agonists in pre-IND Studies

Table 13: RORgamma(T) Antagonists / Inverse Agonists in Preclinical R&D

Table 14: RORgamma(T) Antagonists / Inverse Agonists Discovery Programs

Table 15: RORgamma Agonists Discovery & Development Programs

Table 16: Technology and Pharma Companies with RORgamma Modulator R&D

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists



Companies mentioned in the report

 

4SC Discovery

Advinus Therapeutics

Amgen

Argenta

Arrien Pharmaceuticals

AstraZeneca

Aurigene Discovery Technologies

Biogen

Boehringer Ingelheim

Brickell Biotech

Bristol-Myers Squibb

Celgene

Daiichi Sankyo

Exelixis

Genfit

GlaxoSmithKline

Glenmark Pharmaceuticals

Innovimmune Biotherapeutics

Janssen Biotech

Japan Tobacco

Karo Bio

Lycera

Merck

Nuevolution

ORCA Pharmaceuticals

Orphagen Pharmaceuticals

Pfizer

Phenex Pharmaceuticals

Piramal (& Krish Biotech)

Roche

Takeda Pharmaceutical Co.

Teijin Pharma

Tempero Pharmaceuticals

Visionary Pharmaceuticals

Vitae Pharmaceuticals